INTRODUCTION AND BACKGROUND
Medication safety in oncology practice continues to be a major concern despite advances in technology, system design, and heightened awareness by practitioners. Safe practices for error prevention in oncology have been developing in earnest since a sentinel event in the US in the l990s. 1 Many other articles have continued to provide guidance to practitioners since that point [2] [3] [4] [5] with one of the most recent ones being the ISOPP standards. 6 Practitioners have established policies and processes to improve chemotherapy safety and prevent errors that may lead to patient harm.
One example of an often fatal error is the inadvertent administration of IV vincristine, by the spinal (intrathecal, IT) route. This has occurred more than 55 times since 1968 in a variety of international settings. 7 Trissel et al. reported on the stability of diluted vincristine sulfate and Stefanou et al. reported on administering IV vincristine in minibags. 8, 9 In 2005 the Joint Commission (TJC, formerly known as JCAHO) issued a sentinel event advisory
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1. The labeling of vincristine should include a clear warning label that reads:
2. Syringes should not be used for vincristine administration. 3. Vincristine should where possible be prepared by dilution in small volume intravenous bags (the 'minibag' technique), rather than in a syringe, to protect against accidental administration via a spinal route. 7 Other countries have also provided guidance on safety related to IV vincristine use. 11 In 2006, previous to the WHO alert 115, the Institute for Safe Medication Practices (ISMP) conducted a survey outlining some safety strategies around IV vincristine dispensing and administration. 12 The original 2006 survey results are posted at: http://www.ismp.org/survey/vincristineReports.asp A retrospective study reported on the incidence of extravasation following administration of vinca alkaloids via syringes or minibags. 13 It showed that the reported incidence of vincristine extravasation from syringes was 0.03% (11/37,084) and 0.041% (3/7255) with minibags concluding that minibags could safely be used for administration of vincristine. This led the Hematology Oncology Pharmacy Association (HOPA) www.hoparx.org, International Society of Oncology Pharmacy Practitioners (ISOPP) www.isopp.org, and the Institute for Safe Medication Practices (ISMP) www.ismp.org to collaborate on a survey (hereafter known as 'the survey') to determine (1) the adoption rate of the World Health Organization and ISMP recommendations pertaining to vincristine, (2) the adoption of various other safe practices designed to prevent medication errors with intravenous chemotherapy, and (3) the application of safety and error-prevention strategies when working with oral chemotherapy. The focus on oral chemotherapy was due to the increase in the number of oral chemotherapy drugs and their role in therapy as enabling some cancers to be managed as a chronic disease. This means that the use of some oral chemotherapy drugs can last several years. We wanted to determine if the same medication safety practices designed for parenteral chemotherapy are being adopted for oral chemotherapy. Our overall goal was to provide best practice recommendations in the form of a survey and determine current practices in 2008. Not all recommendations are widely known, but each has been adopted with some success in some parts of the world.
METHODS
A comprehensive survey was developed in collaboration with HOPA, ISOPP, and ISMP. Items included in the 2006 ISMP survey, recommendations from WHO, and TJC were used as background for the survey. The survey used the term 'rule' to refer to WHO recommendations and guidelines. In the results rule and guidelines will be used interchangeably. After testing on a small group of practitioners from three countries, the survey was sent electronically to all HOPA and ISOPP members on April 11, 2008 followed by a reminder notice 2 and 4 weeks later. Simultaneously, ISMP published the survey website in their newsletter (ISMP Medication Safety Alert!) and encouraged anyone interested to participate in the survey. The minimum respondent pool was approximately l000 but had the potential to be larger due to the ISMP newsletter readership. The survey was closed at midnight (EDT/GMT-5) May 19, 2008. The survey requested only one respondent per practice site and a total of 378 responses from 378 different sites were received. There is no way to '. . . awareness alone is not enough. Regardless of the setting in which IV vincristine is dispensed and administered, the relatively easy safety measures mentioned above must be given the highest priority for full implementation. After all, patients rarely survive after IV vincristine has been administered intrathecally, and the subsequent decline until death is slow and excruciatingly painful, both emotionally and physically. No more evidence than this should be needed to raise the urgency with which organizations pursue eradication of this rare but fatal and preventable error.' (ISMP MedicationSafetyAlert! Feb/06) know the potential respondent pool since the survey was widely distributed.
Survey Monkey TM (Portland, OR), a commercial survey instrument was used to develop, collect, and sort responses. Depending on the nature of the question, the reviewers used professional judgment to determine the most appropriate filter parameters. Filters were applied to allow the sorting of data based on responses, using basic 'and,' 'or,' and 'if' logic. Most data were sorted by country of practice (United States vs. World), or site of practice (outpatient clinic vs. inpatient). Survey Monkey TM utilizes logic that 'rounds up' therefore; some data results may total slightly more than 100%. Data analysis was conducted independently by each HOPA, ISOPP, and ISMP representative. A decision was made by the authors to analyze the results from all respondents, the USA, and the rest of the world to look for trends.
RESULTS AND DISCUSSION
Demographics Table 1 shows the respondents by country. The majority of respondents' practice sites were institutional-based practices (85.9%), which were divided between inpatient (53.6% all, 60.4% USA, 48.9% world) and outpatient clinic practices (32.3% all, 37.2% USA, 25.0% world). Based on free text comments, 66 respondents (17.5%) work in both inpatient and outpatient clinics. A small number of respondents practiced in physician office practices (3.5%, all from the USA), and home care (0.8%). The respondents' professional background included pharmacists (87.6%), nurses (7.1%), physicians (1.6%), or administrators and pharmacy technicians (3.7%). The distribution of professions between the USA and world groups was similar.
The goals of the survey were to obtain a baseline on an international scale of how many practice sites were aware of the WHO recommendations and if they may have changed policy within the site, gain an understanding of how many sites followed other safe practice guidelines for chemotherapy, and to see if error prevention strategies were also in place for oral chemotherapy. The potential participants were all HOPA members, ISOPP members, and those reading the ISMP Medication safety Alert! newsletter, thus the response rate is unknown on this particular survey as it was openly shared through ISMP. However, the response was similar in size to the 2006 ISMP survey on vincristine alone which had 417 responses and was distributed only through their newsletter. The ISMP survey did not differentiate between USA and non-USA respondents. Table 2 presents the findings from survey items that addressed the WHO recommendations on IV vincristine. Participants were asked if they were aware of the WHO recommendations, if they had the policy in place, and if it was followed. The results are presented as 'all respondents' and 'USA' or 'world' (non-US) respondents. Results that represent a 10% or greater difference in answers to an individual question between these categories are in bold. The vast majority of respondents were aware of the overall labeling and packaging recommendations for IV vincristine but both awareness and following specific recommendations for labeling, dispensing, and redundant safety checks in the system decreased as more specific questions were asked. There was some variance between 'awareness of the rule' and 'following the rule in practice.' In most cases, once the rule is put into policy there is adherence to the rule in practice with the greatest variance being 9% (vincristine is banned from venopuncture rooms). WHO also had a long-term recommendation that equipment be redesigned so that it is physically impossible to attach an intravenous syringe containing IV vincristine to a spinal needle ('lock and key design') 7 . Although not included in Table 2 , participants were asked about this recommendation and 82.8% of the total respondents believed this is a good idea. However, 53.5% of the total respondents also thought the new design could cause medication errors with other drugs being given via an unintended route, for example, a drug that should be given IT may be given IV. Based on the response 'Always follow the rule,' 3 rules had greater than 80% compliance in practice. They were: (1) IT meds should be packaged differently than IV vincristine, (2) labeling should bear a warning that reads 'For IV only, fatal if given by other routes', and (3) vincristine should be double checked before dispensing. Three (3) rules had 50-60% compliance in practice: (1) IV vincristine should be in the manufacturer provided over wrap, (2) vincristine is prohibited where IT medications are administered, and (3) vincristine is banned from lumbar puncture rooms. Two (2) rules had 40-50% compliance: (1) vincristine should be delivered to an area where IT medications are prohibited, and (2) administration of other IT meds should be complete before dispensing vincristine. Two (2) rules had less than 40% compliance: (1) vincristine should be diluted in at least 50 mL saline and dispensed in a minibag, and (2) vincristine doses should not be administered in a syringe.
WHO recommendations
The two rules with the least compliance were related to administering vincristine in a minibag. Three rules with 40-60% compliance in practice were related to delivery of vincristine to a specific controlled environment. Table 3 lists responses from participants on their experience with implementing WHO guidelines and barriers they have encountered. More than one item could be chosen by the respondents. Of those encountering resistance in implementing the recommendations, most resistance came from nurses (25.4%), followed by physicians (18.7%), pharmacy (7.8%), and the institution (6.9%). Close to 40% of respondents said they had concerns with administering a vesicant as an infusion and 25.4% felt that WHO recommendations were not required since they had other similar safety precautions in place.
The majority of respondents were at least aware of the general WHO recommendations for IV vincristine administration and clearly changes have been made since WHO published their recommendations. Respondents indicated they have changed their practice and the rate of change was documented as 24.1-53.6% depending on the WHO rule. It is encouraging that many responders were already compliant and didn't have to change their policies or practice. Overall once the WHO recommendation was put into place as policy, adherence to the practice followed. This is all encouraging; however there is clearly a long way to go for total compliance.
Two recommendations had greater than 90% awareness; however all of the recommendations had greater than 60.7% awareness with one exception. That exception was that IT meds should be in a manufacturer-provided 'over-wrap' that bears a strong cautionary warning. Manufacturers do not always provide this service and the authors recommend that all manufacturers in all countries adopt this practice.
For a rule to have an impact it must be applied in practice. According to our results seven (7) of the ten (10) recommendations in Table 1 had an overall implementation rate of less than 54%. Three (3) recommendations had greater than 80% compliance. They were: (1) IT meds should be packaged differently than IV vincristine, (2) Figure 1 ) there is from 25.8% to 37.4% improvement in compliance.
The two rules with the least compliance (less than 40%) were related to administering vincristine in a minibag. When compared to the 2006 survey there was only from 2.4% to 18.3% improvement. From analysis of responder comments there were three reasons cited in opposition. (1) Some practitioners are reluctant to administer a vesicant drug as an infusion (IV drip), and perhaps this is a reason why some nurses resist some of the rules. (2) Pediatric practices do not always place central venous lines, and they are reluctant to give vesicant drugs as an infusion. (3) Many practitioners dilute vincristine (e.g., 20-30 mL) and deliver it a large syringe (e.g., 35 mL) believing this would be too large of a volume to give IT and alarm the person administering the drug. It is interesting to note, and is pointed out by responders that Australia was the first country to adopt this rule. While 44.4% of all responders comply with this rule, Australian responders have an 83.3% compliance rate.
Three rules with less than 60% compliance in practice are related to delivery of vincristine to a specific controlled environment. When compared to the 2006 survey there was from 11.4% to 26.3% improvement. From responder comments it is determined that many of these sites infrequently administer IT therapy and their institution is not designed with 'function specific/function restricted' rules. This makes the WHO recommendations related to boldly labeling the final product, and placing them in a vehicle that is difficult to administer via the IT route even more important.
It is somewhat discouraging that only 13.8% of responders cited full implementation of the WHO recommendations with no resistance when implementing. As cited previously, a significant amount of Pediatric concern over giving an infusion (IV drip) vs. IV push
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the resistance was based on concern over giving a vesicant as an infusion (especially in pediatric practices, and especially by nurses). One quarter of the respondents (25.4%) stated they have other similar guidelines in place and have no need for WHO rules. The authors wish to challenge those responders to evaluate the success of their own rules and publish their outcomes. If those guidelines can indeed be documented as effective, they should be shared and compared against existing WHO recommendations.
Responses between the 'USA' and 'world' were very similar, with one significant difference. The USA group reported that nurses resisted the rules (29.4%) more than the world responders (18.6%).
Only 13 respondents (12 pharmacists) represented physician office practices. Responses were similar to other practice sites except for only one respondent who diluted IV vincristine in at least 50 mL saline, and never administered it by syringe. Physician office sites also stated greater resistance to WHO rules by nurses (45.5%), and higher concern over giving a vesicant as an IV infusion (54.5%). Perhaps this explains the tendency to not administer via the IV infusion route noted above. Office practices also reported a higher rate of having alternative policies in place (36.4%).
It is clear that most practices are dealing with some resistance to adopting WHO safety recommendations in their practice. The authors are concerned that this resistance will contribute to another fatal inadvertent administration of IV vincristine by the wrong route. Patients remain at risk and it is prudent to continue to push for full adoption and compliance through: (1) continuing education, (2) encouraging adoption of national laws that are safety oriented, (3) conducting regular surveys to monitor progress, (4) conducting safety-oriented research studies that have both a clinical and financial focus, and (5) publishing patient outcomes so as to monitor progress.
As one respondent summarized in an open comment 'I think that these safety issues that are strongly being implemented by WHO are the very best way to get the management of operations and institutions to have to take a stand. I have not seen changes implemented so quickly and with conviction. I think it's because they send out a direction of how to proceed and everyone is doing it. No-one wants to be the bad guy. It's great for National Action. ' However, another respondent stated what we all know to be reality, 'I, myself, follow these but not everyone in my department does.'
General chemotherapy safety strategies
The second section of the survey asked about general chemotherapy safety strategies and the results are listed in Table 5 . These safe practices were pulled from the literature as well as from experience of the authors' organizations. The results reflect several levels of compliance with 21 items showing greater than 80% adoption by all responders, 10 items with 60-80% adoption, and 4 items with less than 60% adoption.
When compared by average response for each section, the greatest compliance was reported for dispensing (96.1%), followed by dosing (84.6%), drug administration (79.2%), dose ordering (79.1%), and ordering (68.9%). If use of CPOE, which is not widely available, is removed from the ordering section, compliance improves to 72.8% but this section still has the most need for improvement.
The results from the survey (Table 5 ) revealed a rate of adoption of greater than 80% on 21 of the 35 practices presented. Only four practices had less than 60% implementation. One of these items is TALLman lettering, implementation of 49.7%, which the authors believe would be better adopted worldwide if it is supported by all manufacturers and healthcare computer software vendors. The lowest compliance (34%) is computerized order entry, which is expensive to implement and even in healthcare settings with this technology the use of electronic order entry for oncology is not often incorporated due to the complexity of chemotherapy orders. The authors encourage healthcare electronic prescribing software designers to place an emphasis on chemotherapy order entry as their highest priority. Another question asked if the ordering process required 'citing a literature reference' (52.7%). This practice supports evidence-based decision-making, and serves as an additional level of validation for ensuring appropriate dosing. As a bonus in some countries, the literature reference can also help justify reimbursement. Another question asked about the practice of conducting a 'time out' just prior to administering the drug to verify patient, drug, dose, route, and rate of administration. About 58.3% of respondents said that they followed a 'time out' practice. USA respondents adopted this practice at a 10% greater rate than other responders, which could be attributed to the wide push toward this practice to prevent surgical errors in the USA.
Dose-related errors account for many of the serious and fatal medication misadventures. A well-known and published error, which happened in Boston and appears in the 2006 Institute of Medicine report, Preventing Medication Errors as well as many other literature sources, 14, 15 resulted from writing the total course dose along with the total number of days of therapy. This resulted in the total course dose being administered daily and led to the patient's death. This practice is banned by only 70.3% of respondents (70.9% USA, 70.1% world). Another serious concern is that only 2 of 17 recommended practices that are related to Dose Ordering or Dosing had more than 90% compliance. Much work is still required in this most critical step in the chemotherapy process. This is also another opportunity for healthcare software manufacturers to incorporate clinical decision support and ordering standards that make compliance to these recommendations easier to adopt into practice. Table 6 lists results from the survey section on safe practices for oral chemotherapy. Oral chemotherapy is not considered by 32.4% of the responders to require the same safety controls as parenteral chemotherapy. Standards for labeling the drug as 'chemotherapy,' patient education and patient monitoring had 71.8-73.6% adoption from all respondents. However, standards for ensuring order accuracy (58.9% compliance) and safety precautions for preparation of doses (47.9%) show that many practitioners don't process oral chemotherapy with the same concern as they have for parenteral chemotherapy. Hopefully this isn't because of a belief that 'pills are less serious than injections.' Perhaps it is because some of the dispensing is done by a retail pharmacy (18.2%), however, after adjusting for that, there are still less than 75% of the respondents who consider that oral chemotherapy warrants as much concern as parenteral.
Oral chemotherapy safety strategies
There seem to be few differences between the geographic groups. Although the number of respondents was low, 13 physician office practices were similar with most responses however with some exceptions. Office practices provide more patient education (91.5%), and more patient monitoring (100%). They reported better compliance with screening patients prior to therapy to verify dosing weight (84.6%), current height and weight (100%), previous dose adjustments (100%), and current laboratory results (100%). They were less compliant in some ordering processes including allowing verbal orders (31.8%), using pre-printed templates (53.8%), prohibiting the writing of the total patient chemotherapy dose for the entire course (46.2%), defining infusion rates (53.8%), labeling the product as 'chemotherapy' (69.2%), independent calculation of dose by two practitioners (69.2%), and nurse verification of the correct infusion site (53.8%). Some of this may be due to the close working relationship between the physician and office staff. However, it raises concern, especially related to the lack of double checks for doses, use of verbal orders, labeling of products, and the lack of the nurse verifying the correct injection site. Half of the respondents believe that the same rules should apply to oral chemotherapy as apply to parenteral chemotherapy. As expected, most of the oral chemotherapy dispensed by an office practice is through a retail pharmacy (54.5%), or a clinic pharmacy (36.4%). The recent NCCN Task Force Report: Oral Chemotherapy 16 provides a good description of the current state of practice with respect to oral chemotherapy safety. Weingart and colleagues wrote that 'Medication errors are a significant source of concern regarding the administration of chemotherapy. In recent years, a robust infrastructure of checks and balances has been implemented for the administration of parenteral chemotherapy, including templated orders, electronic order-entry systems with decision support, and clinician double-checks. In many academic institutions, every dose of chemotherapy is reviewed by at least 3 or 4 licensed health care providers. Key safety measures include checking calculations of such common parameters as dose per meter squared and estimate of body surface area. Written consent forms are used in some organizations for parenteral chemotherapy. Many comprehensive cancer centers have also developed standard order forms for a variety of chemotherapy regimens. To date, however, fewer controls are built in for oral chemotherapy, so any presumed safety can only be characterized as hypothetical at present. For example, standard order forms generally do not exist for oral chemotherapy. Weingart et al. reported the results of a survey of 42 cancer centers in the United States regarding current safety practices for oral chemotherapy. 17 The information required on a prescription, such as diagnosis, cycle number, and prescription double check by other clinicians, calculation of body surface area or dose per meter squared per body surface area, was variable. Ten of the 42 responding cancer centers had no formal process for monitoring adherence, and 10 centers reported at least 1 serious adverse event in the prior year. The authors concluded that few of the safeguards routinely used for infusion chemotherapy had been adopted for oral chemotherapy at US cancer centers.'
Several practices listed in this survey, and the JNCCN report are also included in the National Patient Safety Goals (NPSG) published in the USA and included in TJC standards that many hospitals are accredited against. 18 Since January 2008 many of these safety goals have been listed as high priority by TJC. Those rules, along with reported % compliance in USA include: (1) no verbal orders for (93.5%), (2) no abbreviations (73.2%), (3) following guidelines for decimals and zeros (94.8%), (4) use of generic names (58.9%), and (5) use of TALLman spelling (67.4%). 
Participant comments
Several representative examples from the 84 open text comments we received are included in Table 7 . These are unedited except to correct spelling errors and to remove personal identifiers. Often the real wisdom provided in a survey is found in the free text comments and the authors encourage you to read them.
Study limitations
The results of this survey reflect the practice of respondents who are affiliated with HOPA, ISOPP, and/or actively read ISMP publications. There is a possibility that the responders disproportionately reflect the practices of those who are more 'safety concerned.' Participants were asked for one response from each site so the respondent may not represent the composite views of all practitioners at the site.
The survey was only provided in English, which probably limited the response rate in some countries. This may have also caused problems with accurately understanding some question and answer choices. The authors encourage countries where English is not widely spoken to translate this survey, administer it and publish their results.
Except for some items in the WHO recommendations section the survey did not have a method for determining the percent adoption of 'all standards' for each practice site, rather it determined the percent adoption of each practice across all sites. In other words, we don't know if anyone has fully adopted all standards, or if anyone has failed to adopt any standards. However, that information may not be critical in determining the primary objective of this survey, which was to benchmark the current rate of adoption of oncology medication safety practices throughout the world. Table 7 . Selected participants comments I think that oral and IV chemo agents should have the same safety and rules of ordering, processing and dispensing irrespective of the indication. We have had two occasions where oral chemo agents were ordered for non-chemo diagnosis at incorrect doses and dispensed. Technician education is vital. Intrathecal procedures should state that technicians can only make one item in the hood at a time. That is, an intrathecal and vincristine should not be made in the same hood at the same time. Peds world things are somewhat different. As an organization we need to step up with a position paper regarding our recommendations for appropriate procedures for dealing with oral chemotherapy and hazardous drugs. We need to create tools to allow institutions to be able to implement these recommendations. They need to be usable in a hospital inpatient/outpatient setting and a physician office (cancer center). In the UK, all aspects of Oral Chemotherapy provision and safety are currently being upgraded/uprated as a result of a UK NPSA (National Patient Safety Agency) initiative, which will generate country wide changes over the next six months. Many questions regarding how people are handling monoclonal antibodies. Qualifications for prescribing chemotherapy??? Do places designated drugs as 'hazardous' and 'chemotherapy'? I believe that we need to implement better safety initiatives for oral chemotherapy, as it is often perceived as 'safer' because of the mere fact that it is an oral formulation. It would be nice to have clear guidelines for ALL chemotherapy dispensing. We do not dispense vincristine as a mini bag piggyback because a lot of our pediatric pts do not have central lines so it is an extravasation issue. I, myself, follow these but not everyone in my department does. Our hospital has been fully compliant with the new Vincristine guidelines. We always put IV Vincristine in minibags/50 mL ns to run over 10 min. All of our oral chemotherapy is dispensed in a separate bag with a chemotherapy caution label on it. I was surprised there was not a question regarding quantities of oral chemotherapy supplied. Exact quantity for a cycle versus manufacturer's original package. The principal problems I witness are (1) Patients (or their caregivers) continuing treatment in the face of unexpected toxicity (and not seeking help) and, (2) Patients taking too much chemotherapy by mistake simply because they have stock in their possession. Due to concern over giving a vesicant as an infusion, we have opted to dilute vincristine to 20 mL in a syringe. The provided over wrap does not fit over this syringe. It is labeled appropriately. Use of electronic medical record for all chemotherapy ordering has increased safety. Physicians order all chemotherapy, pharmacist and nurse checks all chemo orders. Two nurses verify chemo order with final product/label before taking chemotherapy to the patient chair side. There are still challenges with preventing errors even with implementation of EMR. EMR reduces errors, but does not eradicate them. Golden rule on chemotherapy administration always double check independently and then compare. I think it is easier to instigate institutional changes when compliance with guidelines/recommendations are made mandatory by the Department of Health of the country otherwise resistance to changes esp by large groups of staff for example, nursing prevent implementation as there is a 'majority rules' mentality. A prime example is vincristine in minibags -the institution I work in feels the increased nursing time assoc with minibag admin vs syringe admin exceeds the risk reduction benefit.
SUMMARY
The results of this survey provide a new baseline for the adoption rate of safe practice recommendations related to oncology medications. It is encouraging that many safe practices are widely adopted in many settings; however no safe practice is fully implemented in more than 97% of all settings. There are also many safe-practice recommendations that are not widely accepted, including the recommendations by WHO and TJC on the safe use of IV vincristine. Every healthcare practitioner should seriously consider these recommendations and how they can promote their adoption, both in their own practice, and in a broader practice scope. One of the respondents commented that, 'I think it is easier to instigate institutional changes when compliance with guidelines/recommendations are made mandatory by the Department of Health of the country, otherwise resistance to changes, especially by large groups of staff, for example nursing, prevent implementation as there is a 'majority rules' mentality. A prime example is vincristine in minibags -the institution I work in feels the increased nursing time assoc with minibag administration versus syringe administration exceeds the risk reduction benefit. ' Through the use data filters we were able to sort responses and noted that in most cases response trends were consistent across practice settings and countries of practice. The concern therefore is not so much the differences between groups, but why certain safe-practices are not yet adopted by a majority of settings.
From responder feedback it is clear that future surveys or studies should focus attention on: (1) a consensus definition of what constitutes chemotherapy (monoclonal antibodies, biologics, hormonal, oral, etc.), (2) more specific recommendations for the pediatric population, (3) recommendations for drug delivery technology such as IV pumps, (4) safe practices and standards for computer software technology, (5) recommendations for certification standards for practitioners, and (6) further detail on safe practices related to oral chemotherapy.
The future of medication safety is dependent on evidence-based results. The healthcare profession must prove that when safe practices are implemented: (1) patient outcomes improve and (2) overall healthcare costs are justified if not diminished. Clearly more work, and more evaluation is required in documenting the value of safety initiatives. What will it take to get full compliance to proven best practices? Clearly not even national mandates have increased compliance to 100% (e.g., use of minibags for vincristine in Australia, and NPSG standards for ordering in the USA).
One responder commented, 'As an organization we need to step up with a position paper regarding our recommendations for appropriate procedures for dealing with oral chemotherapy and hazardous drugs. We need to create tools to allow institutions to be able to implement these recommendations. They need to be usable in a hospital inpatient/ outpatient setting and a physician office (cancer center).' Patients (and practitioners) remain at risk and it is prudent to continue to push for full adoption and compliance to chemotherapy safety recommendations through: (1) continuing education, (2) encouraging adoption of national laws that are safety oriented, (3) conducting regular surveys to monitor progress, (4) conducting safety-oriented research that has both a clinical and financial focus, and (5) publishing patient outcomes that are both positive and negative so as to monitor progress.
Robert Frost's poem 'Stopping by the Woods on a Snowy Night' provides a fitting conclusion.
The woods are lovely, dark and deep, But I have promises to keep, And miles to go before I sleep, And miles to go before I sleep.
Will we ever fully keep our promise to our patients, to provide safe and effective therapy?
